Enrolling by invitationPhase 2NCT05593588
Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency
Studying OBSOLETE: Common variable immunodeficiency due to TNFR deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Avni Joshi
- Principal Investigator
- Avni Joshi, MD, MSMayo Clinic
- Intervention
- Fisetin(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05593588 on ClinicalTrials.govOther trials for OBSOLETE: Common variable immunodeficiency due to TNFR deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05193552Usage of Spirometry in Managing IgG Therapy in CVID with Airway DiseaseUniversity of Alabama at Birmingham
- RECRUITINGPHASE2NCT02579967Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesNational Cancer Institute (NCI)
See all trials for OBSOLETE: Common variable immunodeficiency due to TNFR deficiency →